ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab
Alliance for Clinical Trials in Oncology
Alliance for Clinical Trials in Oncology
Thomas Jefferson University
Thomas Jefferson University
Mayo Clinic
Assiut University
University of Southern California
Thomas Jefferson University
Mayo Clinic
University of Washington
Vanderbilt-Ingram Cancer Center
Institut Bergonié
Centre Antoine Lacassagne
UNICANCER
M.D. Anderson Cancer Center
Universitaire Ziekenhuizen KU Leuven
University of Nebraska
Alliance for Clinical Trials in Oncology
Jonsson Comprehensive Cancer Center
University of Southern California
Wake Forest University Health Sciences
University of Michigan
University of Michigan
University of Michigan
M.D. Anderson Cancer Center
IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy
Ochsner Health System
National Cancer Institute (NCI)
Peking Union Medical College Hospital
National Cancer Institute (NCI)
National Cancer Institute (NCI)